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Abstract  
Ischaemic diseases remain a major cause of morbidity and mortality despite continuous 
advancements in medical and interventional treatments. Moreover, available drugs reduce 
symptoms associated with tissue ischaemia, without providing a definitive repair. 
Cardiovascular regenerative medicine is an expanding field of research that aims to improve 
the treatment of ischaemic disorders through restorative methods, such as gene therapy, 
stem cell therapy, and tissue engineering. Stem cell transplantation has salutary effects 
through direct and indirect actions, the latter being attributable to growth factors and 
cytokines released by stem cells and influencing the endogenous mechanisms of repair. 
Autologous stem cell therapies offer less scope for intellectual property coverage and have 
limited scalability.  On the other hand, off-the-shelf cell products and derivatives from the 
stem cell secretome have a greater potential for large-scale distribution, thus enticing 
commercial investors and reciprocally producing more significant medical and social 
benefits. This review focuses on the paracrine properties of cardiac stem cells and pericytes, 
two stem cell populations that are increasingly attracting the attention of regenerative 
medicine operators. It is likely that new cardiovascular drugs are introduced in the next 
future by applying different approaches based on the refinement of the stem cell secretome.   
 
 Keywords: Cardiac stem cells. pericytes, secretome, regenerative medicine, drug 
discovery. 
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 Abbreviations: Provide a list of all non-standard abbreviations used three or more times 
in the text, tables, and figure legends. 
 
ABI Family Member 3 Binding Protein (Abi3bp) 
Angiopoietin (Ang)   
Cardiac stem cells (CSCs)  
Cardiosphere-derived cells (CDCs) 
Conditioned medium (CM) 
Coronary heart disease (CHD)  
Dipeptidyl peptidase-4 (DPP-4) 
Embryonic stem cells (ESCs) 
ECs (ECs) 
Endothelial progenitor cells (EPCs) 
Fibroblast growth factor (bFGF) 
Food and Drug Administration (FDA) 
Glucagon-like peptide-1 (GLP1) 
Endothelial progenitor cells (EPCs) 
Endothelial nitric oxide synthase (eNOS) 
Fetal aorta ECs (FAECs)  
Forkhead box protein O1 (FOXO1) 
Granulocyte-colony stimulating factor (G-CSF) 
Heart failure (HF) 
Hepatocyte growth factor (HGF) 
Insulin growth factor-1 (IGF-1) 
Interleukin (IL) 
Hepatocyte growth factor (HGF) 
Human umbilical vascular ECs (HUVECs) 
Metalloproteinases (MMPs),  
Myocardial infarction (MI)  
Monocyte chemoattractant protein-1 (MCP-1) 
Mesenchymal stem cells (MSCs) 
National Health System (NHS) 
Neuregulin 1 (NRG-1) 
Platelet-derived growth factor beta (PDGFβ) 
Secreted frizzled-related protein 1 (sFRP1) 
Stem cell factor (SCF) 
Stromal cell-derived factor-1 (SDF-1) 
Transforming growth factor beta1 (TGF-β1) 
Tumor necrosis factor (TNF-α) 
Tandem Mass Spectrometry Detection (LC-MS/MS) 
Vascular growth factor A (VEGF-A) 
Vascular progenitor cells (VPCs) 
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1. Introduction 
Coronary heart disease (CHD) caused by the narrowing of arteries that feed the heart is the 
UK's single biggest killer, being responsible for ~73,000 deaths each year, an average of 
200 people each day. Acute myocardial infarction (MI) represents the most harmful form of 
CHD. Over the last decade, mortality due to CHD has declined in the UK, but more people 
live with secondary consequences. In fact, most of the current treatments are palliative, i.e. 
they reduce symptoms associated with heart dysfunction, without providing a definitive 
repair. Consequently, CHD patients undergo a progressive decline in the pumping function 
of the heart that ultimately leads to heart failure (HF). Today, post-infarct HF is the leading 
cause of invalidity, hospitalization and mortality in patients over 65. In 2012-13, the UK 
National Health System (NHS) expenditure for cardiovascular disease was £7.02billion, 
63% of which devoted to secondary care (Bhatnagar, Wickramasinghe et al. 2015) The NHS 
analysts have predicted a mismatch between total budget and patient needs of nearly £30 
billion by 2020/21. Therefore, efficiency actions to increase quality and reduce expenditure 
growth are essential for all services, including those for treatment and care of CHD patients. 
However, efficiency alone may not suffice without the introduction of new technologies 
having a transformative impact on this unmet clinical field. 
1.1 The urgent need for new therapies 
 
Current care of CHD comprises pharmacotherapy and revascularisation. However, medical 
treatment can be ineffective as in the case of refractory angina (which has an estimated 
prevalence of 1.8 million in the USA and an incidence of 30-50  000/year in Europe). 
Additionally, a steadily increasing number of patients fall into the category in which 
revascularization cannot be applied or fails because of restenosis. This is especially true of 
patients with occlusive pathology extending to the microcirculation and diabetic or elderly 
patients who have had multiple bypasses and stenting operations. Also, the most important 
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limitation of current treatments is that they do not replace cells irreversibly damaged by 
ischaemia.  
Cardiovascular regenerative medicine is a fast-growing field of research that aims to 
improve the treatment of CHD through innovative restorative methods, such as gene 
therapy, stem cell therapy and tissue engineering (Assmus, Schachinger et al. 2002, 
Wollert, Meyer et al. 2004). Clinical studies with skeletal myoblasts, bone marrow-derived 
cells, mesenchymal stem cells (MSCs) and cardiac stem cells (CSCs) have shown 
feasibility and initial evidence of efficacy (Assmus, Schachinger et al. 2002, Menasche, 
Alfieri et al. 2008, Hare, Traverse et al. 2009, Sant'anna, Kalil et al. 2010, de Jong, 
Houtgraaf et al. 2014). After multiple systematic reviews and meta-analyses, the consensus 
is that transplantation of adult bone marrow cells modestly improves ventricular function, 
infarct size, and remodeling in patients with CHD compared with standard therapy, and 
these benefits persist during long-term follow-up (Martin-Rendon 2016).  Bone marrow 
cell transplantation also reduces the incidence of death, recurrent MI, and stent thrombosis 
in patients with CHD  (Jeevanantham, Butler et al. 2012). Moreover, Steven Chamuleau, 
Andreas Zieher and collegaues have recently utilized interaction models in a multivariable 
fashion to identify subgroups of patients that are defined as potential treatment responders, 
while simultaneously correcting for relevant factors that affect general disease outcome. 
This kind of approach could be the next step towards optimal cell therapy in clinical care 
(Zwetsloot, Gremmels et al. 2016).  
The SCIPIO clinical trial, the first in man to investigate c-kit+ CSCs, reported that 16 
patients with ischemic cardiomyopathy received intracoronary infusions of 0.5-1x10
6
 c-
kit+, autologous CSCs and compared to controls these patients benefited from an 8 and 12 
unit increase in left ventricular ejection fraction, 4 and 12 months after infusion, 
respectively (Bolli et al. 2011).  A subset of 7 patients was subject to cMRI analysis, which 
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showed that the infarct region had significantly decreased in size by ~10g up to 12 months 
following c-kit+ CSC transplantation (Bolli et al. 2011).   
However, there is a persisting dispute regarding the mechanisms underpinning the 
benefit of cell therapy. The direct contribution of transplanted cells in vascular and cardiac 
reconstitution has been questioned (Balsam, Wagers et al. 2004, Murry, Soonpaa et al. 
2004), and presently the concept of paracrine promotion of spontaneous healing processes 
prevails (Gnecchi, He et al. 2005, Tang, Li et al. 2016). Indeed, the general consensus is 
that cell therapy and resultant improvements in cardiac function and decreased infarct size 
in human trials is due to a ‘paracrine’ effect (Tang et al. 2016). However, the lack of 
cardiomyocyte differentiation capability of bone marrow cells or CSCs could be due to 
lack of characterisation of the transplanted cell type, poor cell survival and retention, 
hostile host environment and subsequent restriction of cell proliferation, integration and 
differentiation in this damage-regeneration infarct model.  
Despite the adult mammalian heart being composed of terminally differentiated 
cardiomyocytes that are permanently withdrawn from the cell cycle (Nadal-Ginard 1978, 
Chien and Olson 2002), it is now apparent that the adult heart has the capacity, albeit low, 
to self-renew cardiomyocytes over the human lifespan (Bergmann, Zdunek et al. 2012, 
Bergmann, Zdunek et al. 2015). This is supported by the detection of small, newly-formed, 
immature cardiomyocytes, which incorporate BrdU/EdU and/or stain positive for Ki67, 
Aurora B, and embryonic/neonatal myosin heavy chain, as well as cardiomyocytes 
undergoing mitosis, under normal conditions and in response to diverse pathological and 
physiological stimuli  (Urbanek, Quaini et al. 2003, Urbanek, Torella et al. 2005, Bostrom, 
Mann et al. 2010, Ellison, Vicinanza et al. 2013, Waring, Vicinanza et al. 2014, Bergmann, 
Zdunek et al. 2015). The source of these newly formed cardiomyocytes is a matter of 
debate (Laflamme and Murry 2011). Three main sources of origin of the new 
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cardiomyocytes have been claimed: (a) circulating progenitors, which through the 
bloodstream home to the myocardium and differentiate into cardiomyocytes (Quaini, 
Urbanek et al. 2002); (b) mitotic division of the pre-existing cardiomyocytes (Engel, Hsieh 
et al. 2006, Bersell, Arab et al. 2009, Bostrom, Mann et al. 2010, Senyo, Steinhauser et al. 
2013); and (c) a small population of resident multipotent stem cells able to differentiate 
into the main cell types of the heart (i.e., cardiomyocytes, smooth and endothelial vascular 
and connective tissue cells) (Torella, Ellison et al. 2007, Rasmussen, Frobert et al. 2014).  
Blood-borne precursors, although well documented for having a role in inflammation 
and healing, and when adult mouse bone marrow cells were injected into the chick embryo 
they converted to a myocardial phenotype (Eisenberg, Burch et al. 2006), their 
cardiomyogenic potential in the damaged adult heart is very limited, if any (Loffredo, 
Steinhauser et al. 2011, Ellison, Vicinanza et al. 2013). The evidence so far presented in 
support of re-entry of terminally differentiated cardiomyocytes into the cell cycle has been 
limited to show division of cells that express proteins of the contractile apparatus in their 
cytoplasm (Kuhn, del Monte et al. 2007, Bersell, Arab et al. 2009, Bostrom, Mann et al. 
2010, Senyo, Steinhauser et al. 2013). This evidence is equally compatible with new 
myocyte formation from the pool of multipotent cardiac stem/progenitor cells, which as 
precursor cells express contractile proteins and because newly born myocytes are not yet 
terminally differentiated they are capable of a few rounds of division before irreversibly 
withdrawing from the cell cycle (Nadal-Ginard 1978, Nadal-Ginard, Kajstura et al. 2003). 
However, the mechanisms underlying a strict postmitotic state in the heart during 
pathological remodelling have yet to be fully elucidated (Zebrowski, Becker et al. 2016).  
The best documented source of the small, immature, newly formed cardiomyocytes 
in the adult mammalian heart, including the human (Torella, Ellison et al. 2006), is a small 
population of endogenous cardiac stem and progenitor cells (eCSCs) distributed throughout 
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the atria and ventricles, which are clonogenic, self-renewing and can give rise to functional 
cardiomyocytes and vasculature in vitro and in vivo. Importantly, owing to genetic 
labelling and transitional tracking it is now documented that newly formed cardiomyocytes 
observed in the adult mammalian heart are the product of eCSC differentiation (Hsieh, 
Segers et al. 2007, Ellison, Vicinanza et al. 2013, van Berlo and Molkentin 2014). 
Here, we provide an overview of current knowledge regarding the therapeutic 
potential of using the stem cell-derived secretome instead of source stem cell therapy to 
repair and regenerate the damaged heart. Furthermore, we illustrate methodological aspects 
of secretome-based cardiovascular regenerative medicine, with particular reference to 
functional transcriptomics and proteomics as a combinatory strategy to cherry pick the 
most beneficial components of the stem cell secretome. Finally, we report current evidence 
regarding the salutary aspects of the secretome from two stem cell populations, namely 
CSCs and pericytes. 
2. Generation of a therapeutic product from stem cell secretome  
Stem cells secrete potent combinations of cytokines, growth factors, enzymes, 
microvesicles/exosomes and genetic material, which help cardiac repair and regeneration at 
multiple points. The stem cell secretome supports cardiomyocyte survival and proliferation, 
differentiation of resident stem cells, and neovascularization, while limiting inflammatory 
and pro-fibrotic processes (Gnecchi, He et al. 2005, Baraniak and McDevitt 2010, Zhou, 
Honor et al. 2011, Rao, Aronshtam et al. 2015). Some paracrine factors have pleiotropic 
actions. For instance, one of the key pathways in stem cell-based cardiac repair is the 
stromal cell-derived factor-1 (SDF-1)/CXCR4 axis. It was proposed that substituting SDF-
1 gene therapy for source stem cells might represent a sensible therapeutic approach (Penn 
2009). The blinded placebo-controlled STOP-HF trial demonstrated a single endocardial 
administration of plasmid SDF-1 is safe, attenuates left ventricle remodeling and improves 
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ejection fraction in ischaemic cardiomyopathy (Chung, Miller et al. 2015). However, there 
are also paracrine factors that boost specific responses, thereby providing a more defined 
approach for selective treatments inspired by the stem cell secretome. For instance, 
mesenchymal stem cell-derived Insulin Growth Factor-1 (IGF-1) and ABI Family Member 
3 Binding Protein (Abi3bp) reportedly induce resident CSC mobilization (Mourkioti and 
Rosenthal 2005) and differentiation to the cardiac lineage, (Engels, Rajarajan et al. 2014, 
Hodgkinson, Gomez et al. 2014) while CSC-derived basic Fibroblast Growth Factor 
(bFGF), Vascular Growth Factor-A (VEGF-A) and Hepatocyte Growth Factor (HGF) exert 
potent pro-angiogenic effects (Zhou, Honor et al. 2011, Rao, Aronshtam et al. 2015).  
Intracoronary administration of IGF-1 and HGF, in doses ranging from 0.5 to 2µg 
HGF and 2 to 8µg IGF-1, just below the site of left anterior descendent occlusion, 30 
minutes after MI during coronary reperfusion in the pig, triggered a regenerative response 
from the CSCs, which is potent and able to produce physiologically significant 
regeneration of the damaged myocardium (Ellison, Torella et al. 2011). IGF-1 and HGF 
induced CSC migration, proliferation and functional cardiomyogenic and microvasculature 
differentiation. Furthermore, IGF-1/HGF, in a dose-dependent manner, improved 
cardiomyocyte survival, and reduced fibrosis and cardiomyocyte reactive hypertrophy. 
Interestingly, the effects of a single administration of IGF-1/HGF is still measurable 2 
months after its application, suggesting the existence of a feedback loop triggered by the 
external stimuli that activate the production of growth and survival factors by the targeted 
cells, which explains the persistence and long duration of the regenerative myocardial 
response. These histological changes were correlated with a reduced infarct size and an 
improved ventricular segmental contractility and ejection fraction at the end of the follow-
up assessed by cMRI (Ellison, Torella et al. 2011). 
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Neuregulin-1 (NRG-1) is another key factor implicated in stimulating cardiac repair 
and regeneration (Wadugu and Kuhn 2012, Waring, Vicinanza et al. 2014). An Ig-domain 
containing form of NRG-1β, also known as glial growth factor 2 (GG2) has been shown to 
improve left ventricular ejection fraction and remodelling in pigs post-MI, compared to 
controls (Galindo, Kasasbeh et al. 2014). It is thought that NRG-1 imparts functional 
benefits by activating and increasing eCSC proliferation (Waring, Vicinanza et al. 2014), 
inducing cardiomyocyte replacement (Bersell, Arab et al. 2009, Cohen, Purcell et al. 2014, 
Polizzotti, Ganapathy et al. 2015). A bioengineered hydrogel system enables targeted and 
sustained intramyocardial delivery of NRG-1, activating the cardiomyocyte cell cycle and 
enhancing ventricular function in a murine model of ischemic cardiomyopathy (Cohen, 
Purcell et al. 2014), protecting cardiomyocytes from apoptosis and improving 
mitochondrial function (Galindo, Kasasbeh et al. 2014).  However, the role of NRG-1 in 
inducing cardiomyocyte proliferation in the adult heart has been challenged, with NRG1β1 
treatment not increasing cardiomyocyte DNA synthesis and consequent cardiomyocyte 
renewal in normal or infarcted adult mouse hearts (Reuter, Soonpaa et al. 2014). Therefore, 
the role of NRG-1 administration in inducing cardiomyocyte proliferation and replacement 
in the adult failing heart remains controversial.  
The stem cell secretome is collected in a form of cell culture conditioned medium 
(CM) or supernatant. The use of stem cell-derived secretome has several advantages 
compared to the use of stem cells, as CM can be manufactured, sterilized, freeze-dried, 
packaged, stored and transported more easily. Therefore, the stem cell-derived secretome 
has a promising prospect to become a successful pharmaceutical/medicinal product for 
regenerative medicine. On the other hand, variability represents a major limitation. The 
first level of inconsistency is represented by inter-individual variability, due to the patient’s 
characteristics.  Culture conditions, growth media and passages also affect the composition 
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of CM, as recently reviewed (Pawitan 2014). In some occasions, changes in culture 
conditions are intentionally introduced to enhance the production of certain biological 
components. For instance, stem cells could be exposed to hypoxic conditions, with the aim 
of stimulating the production of growth factors (Di Santo, Yang et al. 2009, Ranganath, 
Levy et al. 2012). The three-dimensional spheroid culture of human adipose-derived stem 
cells with clinically relevant medium composed of amino acids, vitamins, glucose, and 
human serum leads to 23- to 27-fold higher production of angiogenic factors than that by 
conventional monolayer culture (Bhang, Lee et al. 2014). On the other hand, the purity of 
preparations may become an issue when complete growth medium is used, or collection of 
CM is performed shortly after removal of growth medium supplements. In this case, 
contamination may derive from the presence of left-over serum carrier proteins, due to 
dynamic recycling of extracellular proteins by cellular vesicles (Iso, Rao et al. 2014). The 
presence of serum or culture media in the CM- or supernatant-derived product might elicit 
immune responses and/or side effects. In this respect, alternative methods to culture cells 
(such as the adoption of serum-free culture, etc) and the refinement of the CM-derived 
secretome products should be considered. However, a recent study indicates that the 
formation of complexes of serum-derived immunoglobulins with paracrine factors could 
enhance the stability and biological activity of the CM therapeutic component (Rao, 
Aronshtam et al. 2015). A challenging objective of future research is to define the whole 
composition of crude CM preparations, measure activity of the main components and 
determine therapeutic doses. In this respect, manufacturing and quality control protocols 
need to be further refined and standardized to accomplish the classical regulatory path for 
drugs. The goal is to generate synthetic versions, inspired by the stem cell secretome, 
containing consistent dosages of therapeutic factors for the treatment of thousand patients.  
2.1 Methodologies to determine the therapeutic component  
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Different methods have been used for studying the secretome composition and for 
distinguishing the essential components that are advantageous for therapeutic applications. 
Multiplex antibody-based techniques, such as antibody arrays, have high sensitivity (in the 
range of 1–10 pg/ml), specificity, and reproducibility across a broad range of 
concentrations. High-throughput analysis of the human MSC secretome using a human 
cytokine antibody array has identified about 40 proteins with high expression levels 
(Parekkadan, van Poll et al. 2007). Studies using multiplex antibody-based arrays showed 
the contribution of MSC-derived paracrine factors in determining cardiac improvement in a 
swine MI models (Nguyen, Maltais et al. 2010) and the participation of angiogenin, a 
secreted ribonuclease that inhibits protein translation under stress conditions, in promotion 
of cardiomyocyte survival by intramyocardially injected bone marrow-derived 
mononuclear cells (Ascione, Rowlinson et al. 2015). However, a common drawback of 
antibody-based techniques (e.g., ELISA and antibody arrays) consists of the limited 
availability of antibodies to detect secreted proteins. 
Liquid Chromatography with Tandem Mass Spectrometry Detection (LC-MS/MS) 
has been widely used for characterizing the secretome profile. For example, a study using 
this technique demonstrated that preconditioning of human adipose-derived MSCs with 
Tumor Necrosis Factor-alpha (TNF-α) leads to enhanced expression of cytokines and 
chemokines such as Interleukin-6 (IL-6), Interleukin-8 (IL-8), Monocyte chemoattractant 
protein-1 (MCP-1), metalloproteinases (MMPs), Pentraxin-related protein, and Cathepsin L 
in CM (Lee, Kim et al. 2010). On the other hand, gel-based and LC-MS/MS techniques 
have limited sensitivity to detect molecules that are present in fmol concentrations 
(Ranganath, Levy et al. 2012).  
RNA interference, by siRNA or shRNA, represents a powerful method to evaluate 
the function of candidate genes (Lemons, Maurya et al. 2013). Throughput interference 
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screening of mRNAs and microRNAs in cell-based assays can also help to decipher the 
functional importance of single components of the stem cells secretome. It is necessary to 
validate the outcome of silencing by rescue experiments where the CM from silenced cells 
is supplemented with a candidate recombinant protein to determine if it restores the 
original phenotype. Figure 1 illustrates an application of siRNA technology to the 
discovery of CM components implicated in the activation of stem cell migration.  
A more systematic approach to tackling the secretome complexity combines LC-
MS/MS detection, antibody arrays, microarrays, and bioinformatics. This approach 
identified 201 unique proteins (132 using LC-MS/MS and 72 using antibody arrays) typical 
of human MSC secretome  (Sze, de Kleijn et al. 2007). Also, Sze exploited a computational 
analysis of data to predict the roles of the secretome components in metabolism, immune 
response, and development. 
2.2  Pre-clinical cardiovascular studies using stem cell-derived  secretome   
Some preclinical studies have demonstrated that delivery of stem cell-derived CM has 
salutary effects in models of limb and myocardial ischaemia. Table 1 summarizes some 
fundamental investigations that evaluated the effect of crude CM preparations. A study 
using an intra-muscular injection of endothelial progenitor cell-derived CM (EPC-CM) 
collected under hypoxia showed outcomes (i.e. tissue revascularization and functional 
recovery) similar to cell transplantation in a model of limb ischaemia  (Di Santo, Yang et 
al. 2009). Similar benefits have been reported with the use of CM from human amniotic 
fluid stem cells (Mirabella, Cilli et al. 2012), cord blood-derived EPCs (Kim, Song et al. 
2010) and foetal aorta CD133 vascular cells (Barcelos, Duplaa et al. 2009) in limb 
ischaemia and wound healing models and with CM from EPCs (Hynes, Kumar et al. 2013) 
and MSCs in MI (Timmers, Lim et al. 2007, See, Seki et al. 2011, Timmers, Lim et al. 
2011, Yang, Wang et al. 2013). Furthermore, the CM of human embryonic stem cell-
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derived ECs reportedly restored the healing activity of circulating proangiogenic cells from 
diabetic patients upon combined injection in ischaemic limbs of severe combined 
immunodeficient mice (Ho, Lai et al. 2012). One important limitation of using CM for 
therapeutic uses consists of the rapid degradation of therapeutic components in vivo. To 
obviate this drawback, some investigators have used repeated injections of the CM in 
preclinical studies, but this approach may be unpractical for clinical applications. We have 
shown that perivascular transplantation of micro-incapsulated glucagon like peptide-1 
(GLP1)-expressing stem cells enables long-lasting cell retention in the ischaemic site as 
well as prolonged paracrine activity, resulting in robust limb arteriogenesis (Katare, Riu et 
al. 2013). Results of cytometric bead arrays on tissue collected 1 week after implantation 
showed the expression of human angiogenic proteins in ischaemic muscles, indicating the 
persistence of paracrinally active human cells.  
Growing evidence suggests stem cells used in regenerative medicine secrete some 
form of extracellular vesicles, including microvesicles and exosomes. Exosomes represent 
a relatively homogeneous subset of secreted membrane vesicles that are formed by direct 
budding of the plasma membrane into early endosomes (Sahoo and Losordo 2014). 
Exosomes derived from stem cells activate angiogenesis and cytoprotection and modulate 
inflammation and apoptosis (Sahoo, Klychko et al. 2011, Lee, Mitsialis et al. 2012, 
Mackie, Klyachko et al. 2012). Seminal preclinical studies from Sahoo et al. have shown 
that exosomes may represent a significant component of the paracrine effect of stem cell 
transplantation for therapeutic angiogenesis (Sahoo, Klychko et al. 2011). Important 
insights are also emerging from mechanistic studies. Exosomes derived from various stem 
cells enhance the myocardial viability and prevent adverse heart remodeling through a 
reduction in oxidative stress and Akt activation (Arslan, Lai et al. 2013). Furthermore, 
exciting new research suggests that exosomes directly communicate with the target cells by 
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delivering specific microRNAs and other small RNAs characteristic of their parental cell of 
origin (Yuan, Farber et al. 2009, Mackie, Klyachko et al. 2012). Analysis of microRNAs 
expression in embryonic stem cell-derived exosomes revealed high expression of 
embryonic-specific microRNAs belonging to the miR-294 family. This microRNA 
regulates fundamental properties of embryonic stem cells (ESCs), including pluripotency, 
cell cycle, and proliferation and participates in the beneficial effect of ESC-derived 
exosomes transplantation in the injured heart (Khan, Nickoloff et al. 2015). A recent study 
showed the pathogenic communication between vascular ECs and pericytes in the diabetic 
microvasculature is mediated by the shedding of endothelial microparticles carrying miR-
503, which transfer miR-503 from ECs to vascular pericytes (Caporali, Meloni et al. 2015). 
To date, no clinical trial employing stem cell-derived CM for the treatment of 
cardiovascular disease has been reported. Two pilot studies described potential therapeutic 
activity of MSC CM for hair follicle regeneration and resurfacing wound healing in 
humans (Zhou, Xu et al. 2013, Fukuoka and Suga 2015, Shin, Ryu et al. 2015). These 
initial trials are expected to encourage clinical studies for the treatment of cardiovascular 
patients. 
2.3 Commercialization of the stem cell secretome 
The stem cell secretome is receiving increasing attention not only from researchers but also 
from industry. Recently, US-based stem cell therapeutic company Stemedica announced 
worldwide manufacturing license of VitriLife to their subsidiary StemProtein (Source: 
Stemedica Cell Technologies, Inc.). The patent covers a novel vaporization technology that 
immobilizes biologicals in glassy carbohydrates (a VitriLife™ state) thus allowing storage 
at room temperature for several years. The company claims VitriLife-preserved proteins 
are superior in activity compared to lyophilized proteins. The thermostable mixture from 
VitriLife processed stem cell-derived CM contains therapeutic biologicals, such as 
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cytokines, chemokines, growth factors, proteins, mRNAs, and microRNAs. The new 
technology may provide an efficient way for converting stem cell-derived factors into 
powders that retain natural efficacy for eventual bulk processing and packaging of product 
and delivery to medical markets. Stemedica has plans to commercialize the product for 
many disease conditions, from skin problems to Alzheimer’s disease, but has not released 
yet any information about regulatory status. 
Stem cell-derived CM in cosmetic products has been commercialized and sold world-
wide. Examples include Regenica cream made with Human Fibroblast Serum Free CM by 
SkinMedica, anti-aging non-embryonic stem cell extracts manufactured by Lifeline Skin 
Care,  stabilized CM from placenta- and umbilical cord-derived human stem cells from 
Blue Horizon,  and serum-free adipose-derived MSC CM from Celprogen.   
The regulatory process of CM-derived products remains vague. Despite the fact stem 
cell-derived cosmetic products have been commercialized for a decade as components of 
skin creams, only recently Food and Drug Administration (FDA) has pronounced a 
statement that these compounds should be considered drugs under the Federal Food, Drug, 
and Cosmetic Act (http://www.ipscell.com/2016/08/3-more-fda-warning-letters-to-stem-
cell-cosmetics-makers/). Therefore, marketing of these products with claims evidencing the 
use in the diagnosis, cure, mitigation, treatment, or prevention of disease violates the Act. 
If this applies to skin creams, even more stringent regulation should be installed for the 
therapeutic use of CM in human cardiovascular diseases. 
3. Exploiting the secretome of CSCs and pericytes for cardiovascular repair 
One important caveat of secretome-based therapy is represented by the specificity of the 
source cell about the target tissue. It is, in fact, more likely that a therapeutic effect is 
achieved by exploiting the paracrine activity of tissue-specific cells rather than using cells 
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isolated from a different tissue. In this respect, CSCs and pericytes may be uniquely suited 
to produce paracrine factors instrumental to cardiac and vascular repair and regeneration. 
The first report of CSCs able to repopulate the adult heart was in 2003 (Beltrami, 
Barlucchi et al. 2003). Following this initial report, several cardiac stem/progenitor cell 
types have been identified based on the specification of membrane markers and transcription 
factors and resident CSCs exhibit spontaneous regenerative capacity when tested in an 
appropriate injury model (Ellison, Vicinanza et al. 2013).  Table 2 provides a summary of 
different CSC subtypes based on antigenic characteristics.   
Pericytes are mural cells that encircle capillaries in different organs. Pericyte-like cells 
that express stem cell markers and possess clonogenic expansion capacity have been 
identified in the adventitia of large vessels from human fetuses (Invernici, Emanueli et al. 
2007) and adult individuals (Campagnolo, Cesselli et al. 2010). They share several markers 
that are typical of microvascular pericytes but do not express the surface marker CD146 
(Table 3). Preclinical studies have shown that transplantation of microvascular pericytes 
and adventitial pericyte-like stem cells exert therapeutic actions in models of myocardial 
(Katare, Riu et al. 2011, Chen, Okada et al. 2013, Avolio, Meloni et al. 2015) and peripheral 
ischaemia (Campagnolo, Cesselli et al. 2010, Dar, Domev et al. 2012, Gubernator, Slater et 
al. 2015). In the infarcted mouse heart, combined transplantation of human adventitial 
pericyte-like stem cells and CSCs, reduced the infarct size and improved indexes of 
contractility by the promotion of angiogenesis, inhibition of cardiomyocyte apoptosis, and 
attraction of resident and circulating reparative cells (Avolio, Meloni et al. 2015). 
The ultimate goal for heart repair and regeneration is to restore muscle mass, and new 
cardiomyocyte formation following cell transplantation or ‘paracrine’ cardiac regenerative 
growth factor overexpression or administration has been demonstrated in different animal 
models of MI (Nadal-Ginard 1978, Nadal-Ginard, Kajstura et al. 2003, Limana, Zacheo et 
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al. 2007, Hatzistergos, Quevedo et al. 2010, Ellison, Torella et al. 2011, Loffredo, 
Steinhauser et al. 2011, Madonna and De Caterina 2011, Koudstaal, Bastings et al. 2014, 
Wei, Serpooshan et al. 2015, Martin-Rendon 2016, Tang, Li et al. 2016). Whether these 
newly formed cardiomyocytes derive from re-entry of the cell cycle of pre-existing 
cardiomyocytes, or more likely from the resident eCSC population (Loffredo, Steinhauser et 
al. 2011), has yet to be determined. Moreover, there are a number of technical limitations to 
prove myogenesis in these models, and the reader is directed to comprehensive reviews on 
this subject (Zebrowski, Becker et al. 2016).   
 
3.1 Evidence for paracrine healing properties of pericytes  
In 2007, Invernici et al. (Invernici, Emanueli et al. 2007) reported the identification of a 
population of pericyte-like cells in the human fetal aorta composed of undifferentiated 
mesenchymal cells that coexpress endothelial and myogenic markers. Following 
supplementation of the culture medium with VEGF-A or Platelet-derived Growth Factor 
beta (PDGFβ), these cells gave rise to a mixed population of mature endothelial and mural 
cells. In consideration of the vascular lineage commitment, Invernici named fetal aorta-
derived cells with the term vascular progenitor cells (VPCs). Undifferentiated VPCs 
produce large amounts of immunoreactive VEGF-A and Angiopoietin-2 (Ang-2). 
Interestingly, the paracrine pattern was profoundly altered on serum-induced VPC 
differentiation. In fact, in the differentiated cell CM, the VEGF-A amount was negligible, 
whereas Ang-2 and SDF-1 reached 3.5- and 7.0-fold higher levels than in the CM of 
undifferentiated cells. These results indicate that VPCs produce angiogenic factors and that 
the concentration of these factors in the CM varies according to cell maturation. The 
angiogenic properties of human VPC CM were confirmed in an in vitro proliferation assay 
with human endothelial cells (ECs). The CM from VPCs stimulated the growth of both 
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human umbilical vascular ECs (HUVECs) and fetal aorta ECs (FAECs), whereas CM 
produced by VPCs on differentiation was ineffective. The complex angiogenic composition 
of VPC-derived CM was confirmed because its proangiogenic effect was reduced, but not 
abolished, by the addition of anti-VEGF-A antibodies. In a subsequent study investigating 
the therapeutic activity of human VPCs in ischemic wound healing, Barcelos et al. 
(Barcelos, Duplaa et al. 2009) used a cytokine bead array to identify additional 
proangiogenic factors. They found that undifferentiated VPCs secrete high levels of IL-6 
and IL-8, VEGF-A, granulocyte-colony stimulating factor (G-CSF) and MCP-1. 
Administration of the CM from undifferentiated VPCs instead of cells supported wound 
closure and neovascularization in mice, whereas the CM of differentiated VPCs was 
ineffective. Furthermore, neutralizing antibodies against VEGF-A or IL-8 inhibited the 
healing effect of VPC-derived CM, thus confirming the key role of both factors in wound 
closure and capillarization, whereas capturing IL-6 was ineffective. Importantly, the study 
delineated the signaling pathway activated by the VPC secretome in target cells. In fact, 
VPC-derived CM induced the phosphorylation of Akt at Ser473 as well as of endothelial 
nitric oxide synthase (eNOS) and Forkhead box protein O1 (FOXO1) in HUVECs. Also, 
transfection of HUVECs with dominant-negative Akt remarkably reduced the pro-survival 
effect of CM. In consideration of the link between the VEGF-A and Wnt pathways, 
Barcelos further explored the involvement of Wnt in the promotion of angiogenesis by 
VPCs. They found that the Wnt antagonist Secreted frizzled-related protein 1 (sFRP1), but 
not Dkk-1 an inhibitor of the canonical Wnt signaling pathway, abolishes the facilitation of 
wound closure and reparative angiogenesis by VPC-derived CM. The editorial comment to 
Barcelos’ study (Chen, Saparov et al. 2014) highlights this was the first to demonstrate the 
efficacy and associated healing mechanisms of topical therapy with human progenitor cell-
derived CM in a preclinical model of diabetic ischemic foot ulcer. Adding a level of 
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complexity to this system, miR-15a and miR-16-1 can antagonize Wnt signaling (Bonci, 
Coppola et al. 2008). Importantly, the two microRNAs impair the biological functions of 
proangiogenic cells, and their expression is increased in the proangiogenic cells and serum 
of patients with critical limb ischaemia (Spinetti, Fortunato et al. 2013). 
Pericyte-like cells isolated and expanded from the adult saphenous vein produce 
large amounts of angiogenic factors, in particular, VEGF-A, VEGF-B, Ang-1, and miR-132, 
which are delivered to neighboring ECs through the establishment of integrin-mediated 
interactions (Campagnolo, Cesselli et al. 2010, Katare, Riu et al. 2011). Secretion of VEGF-
A, Ang-1 and miR-132 is further augmented by hypoxia/starvation, which mimics in vitro 
the environment encountered by cells upon transplantation into ischaemic tissues (Katare, 
Riu et al. 2011). Importantly, anti-miR-132-transfected pericytes were inferior to naïve 
pericytes or scrambled-transfected pericytes in improving reparative angiogenesis in the 
infarcted mouse heart. Nonetheless, the improvement afforded by pericytes was not 
completely abrogated by the miR-132 silencing, thus suggesting the participation of miR-
132-dependent and independent mechanisms (Katare, Riu et al. 2011). Figure 2 summarizes 
the spectrum of the in vivo paracrine interactions between transplanted pericytes and 
resident cardiomyocytes, CSCs, and ECs.  
It has been acknowledged that direct contact and paracrine signaling between 
different stem cell populations can induce functional changes and influence the 
susceptibility to a variety of stressors. Also, competitive interaction between stem cells 
within their native niches reportedly results in survival of the fittest stem cells and death of 
the most susceptible cells (Leri and Anversa 2013).  We further elaborated this intriguing 
concept by assessing the reciprocal cross-talk between saphenous vein-derived pericytes and 
c-Kit CSCs (Avolio, Meloni et al. 2015). Intra-myocardial injection of adventitial pericytes 
or CSCs, as a single or combined therapy, increases the abundance of primitive c-Kit+ cells 
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in the peri-infarct zone. Also, the CM of the 2 populations exerts a potent chemoattractant 
activity on murine CSCs, without influencing their proliferation or viability. The two cell 
populations release similar levels of Hepatocyte Growth Factor (HGF) and stem cell factor 
(SCF), with no substantial changes in normoxia versus hypoxia or monoculture versus 
coculture. On the other hand, pericytes secrete the proangiogenic factors Ang-1 and Ang-2 
at higher concentrations than CSCs, and a similar trend was observed with bFGF. 
Interestingly, the secretion of angiopoietins and bFGF by cells in coculture was lower than 
the average of the 2 cell preparations, thus indicating a negative reciprocal interference. 
Moreover, hypoxia induced an increase in the secretion of VEGF-A by CSCs, but this effect 
was not appreeeciated in the coculture. Concerning miR-132 secretion, hypoxia increased its 
level in pericyte CM, while reducing it CSC CM. An additive effect of the cell coculture 
was instead noted in the secretion of SDF-1α both under normoxia and hypoxia. Altogether, 
these data indicate a multifaceted interactive behavior at the level of secretome, which may 
result in attenuated secretion of VEGF-A, Ang-1, Ang-2, bFGF, and miR-132 in comparison 
with the prominent cell producer, but the synergic release of SDF-1. To determine whether 
these phenomena are transcriptionally modulated, we performed quantitative polymerase 
chain reaction analyses of angiopoietins and SDF-1 mRNA levels in pericytes and CSCs, 
before and after exposure to each other’s CM. Results indicate CM reduces the expression 
of Ang-2 in both the cell types. Also, CSCs exposed to pericyte CM showed reduced SDF-1 
mRNA levels as compared with CSCs exposed to the unconditioned medium. These data 
suggest a transcriptional interference on Ang-2 and SDF-1. However, while Ang-2 
expression was reduced at mRNA and protein level, the increase in SDF-1 content in 
coculture media was not attributed to the induction of gene transcription, but rather to an 
increase in secretion rate. Exploring a possible involvement of Dipeptidyl peptidase-4 (DPP-
4) we found higher expression levels by CSCs. Furthermore, DPP-4 is downregulated at 
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mRNA and protein level in CSCs exposed to pericytes CM. These findings may have 
important implication for association cell therapy, where the outcome may depend on the 
balance between cooperative and competitive interactions at the level of the secretome. For 
instance, in our study, the combined transplantation of pericytes and CSCs additively 
reduced the infarct size and promoted vascular proliferation and arteriogenesis, but did not 
surpass single therapies concerning contractility indexes (Avolio, Meloni et al. 2015). 
Skeletal muscle-derived stem cells have been among the first cell therapy models for 
regenerative treatment of the infarcted heart (Menasche 2008). A recent study  investigated 
the therapeutic potential of human skeletal muscle pericytes for treating ischaemic heart 
disease and mediating associated repair mechanisms in mice (Chen, Okada et al. 2013). The 
authors found that pericyte transplantation attenuates left ventricular dilatation and 
myocardial fibrosis and improves cardiac contractility in infarcted mouse hearts. In line with 
findings in saphenous vein-derived pericytes, hypoxia-induced the expression of VEGF-A 
as well as PDGF-β, Transforming Growth Factor beta1 (TGF-β1), and corresponding 
receptors while expression of bFGF, HGF, and Ang-1 was repressed. 
3.2 Resident cardiac pericytes: are they better suited for the heart?   
New knowledge on microvessel-associated regenerative precursor cells in cardiac muscle 
opens prospectives for organ-specific treatments of patients with congenital and acquired 
heart defects. Peault’s team showed that microvascular pericytes within the human 
myocardium exhibit phenotypes and multipotency similar to their anatomically and 
developmentally distinct counterparts (Chen, Baily et al. 2015). However, they have no 
ability for skeletal myogenesis, diverging in this respect from pericytes of all other origins. 
In contrast, a cardiomyogenic potential was evidenced both in vitro and after intra-
myocardial transplantation in vivo.  
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Using the same standard operating protocol employed for the derivation of pericytes 
from adult saphenous veins, we have isolated and expanded pericyte-like progenitors from 
small biopsies of congenitally defective hearts (antigenic features illustrated in Table 3) 
(Avolio, Rodriguez-Arabaolaza et al. 2015). The long-term objective of research on 
neonatal cardiac pericytes is their perusal for definitive correction of congenital heart 
defects (Avolio, Caputo et al. 2015). A spectrum of prostheses in the form of conduits, 
patches, and valves is employed in congenital cardiac surgery, but none of them is perfect. 
In particular, currently, available grafts do not possess growing capacity and become 
incompetent with time, thus requiring surgical replacement. The basic concept of tissue 
engineering is to create living material made by cellularized grafts that, once implanted into 
the heart, grows and remodels in parallel with the recipient organ. Neonatal pericytes 
produce a powerful secretome uniquely fit for the purpose. This includes growth factors that 
promote vasculogenesis and cardiomyogenesis and chemokines able to attract ECs and 
endothelial progenitor cells instrumental to graft endothelialisation. Comparison with 
saphenous vein–derived pericytes indicates similarity of the 2 cell populations, though 
cardiac pericytes secrete more HGF (6-fold), Ang-2 (8-fold), bFGF (4-fold), and VEGF-A 
(6-fold) than saphenous vein–derived pericytes. Furthermore, neonatal cardiac pericytes 
release procollagen type 1, a major constituent of the cardiac extracellular matrix, which is 
fundamental to the maintenance of graft integrity.  
The umbilical cord represents a valuable source of stem cells immediately available 
at birth for corrective strategies. In a recent study, human cord-derived pericytes or cord 
blood-derived MSCs were delivered before or after alveolar injury into the airways of 
newborn rats exposed to hyperoxia, a model of bronchopulmonary dysplasia which 
complicates extreme prematurity and currently lacks efficient treatment (Pierro, Ionescu et 
al. 2013). Rat pups exposed to hyperoxia showed typical alteration in alveolar growth with 
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enlargement and loss of lung capillaries. Both human cord-derived pericytes and cord 
blood-derived MSCs partially prevented and rescued lung function and structure. However, 
the low cell engraftment suggested a paracrine effect. In line, cell free-derived CM from 
both cell types manifested significant benefit when used either prophylactically or 
therapeutically. Altogether, these studies open new avenues to exploit pericytes in neonatal 
regenerative medicine. 
4. Evidence for paracrine healing properties of cardiac stem/progenitor 
cells  
There is a growing consensus that the beneficial effects of any myocardial autologous 
or allogeneic cell therapy so far tested is, at least in part, mediated by a paracrine effect on 
the patient’s cells at risk and activation of the host’s CSCs by growth factors secreted by the 
transplanted cells (Lorkeers, Eding et al. 2014); (Braunwald 2015). Major contributors to 
this cardioprotective and CSC stimulatory effect are HGF and IGF-1 acting through their 
relative receptors present both on the myocytes, vascular and CSCs of the recipient's heart 
(Ellison, Torella et al. 2011). 
MSCs have a broad repertoire of secreted trophic and immunomodulatory cytokines; 
however, they also secrete factors that negatively modulate cardiomyocyte apoptosis, 
inflammation, scar formation, and pathological remodeling (Ranganath, Levy et al. 2012).  
Moreover, it is questionable whether they are the most optimal cell to use regarding survival 
and homing to and engraftment in the myocardium. Furthermore, cells can become 
entrapped in the microvasculature and impede cell entry into the myocardium. 
The safety and efficacy of transplanting 2 million allogeneic, mismatched 
Cardiosphere-derived cells (CDCs) was tested in infarcted rats. Three weeks post-MI, 
animals that received allogeneic CDCs exhibited smaller scar size, increased infarcted wall 
thickness, and attenuation of ventricular remodeling. Allogeneic CDC transplantation 
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resulted in an improved fractional area change (∼12 %), ejection fraction (∼20 %), and 
fractional shortening (∼10 %), and this was sustained for at least 6 months. Furthermore, 
allogeneic CDCs stimulated endogenous regenerative mechanisms (cardiomyocyte cycling, 
recruitment of endogenous CSCs, angiogenesis) and increased levels of myocardial VEGF, 
IGF-1, and HGF (Malliaras, Makkar et al. 2014).  
We have previously shown that CSCs that express high levels of the transcription 
factor GATA-4 exert a paracrine survival effect on cardiomyocytes through increased IGF-1 
secretion and induction of the IGF-1R signaling pathway (Kawaguchi, Smith et al. 2010). 
Furthermore, unlike bone marrow derived cells (Hofmann, Wollert et al. 2005), CSCs have 
a very high tropism for the myocardium (Ellison, Vicinanza et al. 2013). This cardiac 
tropism is governed by the SDF1-CXCR4 signaling axis, and when CSCs are injected either 
intracoronary or systemically, they home to and nest into the damaged heart with a high 
efficiency and significantly restore the myocardium, anatomically and functionally (Ellison, 
Vicinanza et al. 2013). 
Cloned male eGFP-transduced heterologous HLA not-matched porcine CSCs, were 
administered intracoronary at differential doses (5x10
6
, 5x10
7
 and 1x10
8
) in 3 groups of 
pigs, 30 minutes after coronary reperfusion. Pig serum was injected to 6 control pigs after 
MI. BrdU was administered via osmotic pumps to track myocardial regeneration. Pigs were 
sacrificed at 30 min, 1 and 21 days. We found that heterologous CSC administration was 
well tolerated and without adverse effects. CSCs nested into the damaged myocardium with 
an efficiency of >95%, at 30 minutes through to 1 day after MI. Minimal spill over of CSCs 
was detected in the coronary sinus, spleen, lung or live and all injected CSCs had 
disappeared from the myocardium at 21 days. CSC-treated infarcted pig hearts showed a 
significant increase in the number of endogenous c-kit
pos
 (GFP
neg
) CSCs in the border and 
infarct regions, compared to CTRL. CSC-treated hearts exhibited an increase in the number 
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of small, newly formed BrdU
pos
 myocytes and capillaries.  CSC injection significantly 
preserved myocardial wall structure and attenuated remodeling by reducing hypertrophy, 
apoptosis and fibrosis (Figure 3). Moreover, cardiac function was significantly 
preserved/improved by heterologous CSC-treatment. To summarize, intracoronary injection 
of heterologous CSCs after MI in pigs, which is a clinically relevant MI model, activates the 
endogenous CSCs through a paracrine mechanism resulting in improved myocardial cell 
survival and physiologically meaningful regeneration (Ellison, Torella et al. 2009). 
Allogeneic CSC therapy is conceptually and practically different from any presently in 
clinical use. The proposed cell therapy is only a different form of growth factor therapy, 
where the cells naturally home to the damaged myocardium, deliver a more complex 
mixture of growth factors, elicit a ‘paracrine’ effect and activate the endogenous target cells. 
Then the allogeneic CSCs are eliminated, and the regeneration triggered by activated 
endogenous CSCs is completely autologous. Therefore, the allogeneic CSCs survived long 
enough in the allogeneic host to produce their paracrine effect before being eliminated by 
the host immune system. Once more information is available, the allogeneic cells could be 
used either alone or in combination with the available factor therapy to improve the 
activation of the CSCs and the maturation of their progeny. 
5. Conclusions 
The market analysis predicts protein and peptide-based drugs will compose >50% of 
novel drugs within the next 10 years. Pharmacological companies have been using unbiased 
discovery methods to generate new druggable compounds since many years. The approach 
is now increasingly used in academic research. It is likely that new cardiovascular drugs will 
be introduced in the next future by applying these approaches to the study of stem cell 
paracrine function. Due to the variability of the product and high costs associated with 
clinical grade production, stem cell-based therapy is not amenable to the majority of 
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ischaemic patients. The use of drugs inspired by the stem cell secretome will instead offer 
unprecedented therapeutic opportunities, resulting in a fundamental shift in the initial 
concept of regenerative medicine.   
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Figure legends 
 
Figure 1: Cardiac stem cell migration-based siRNA secretome screening. (1) Source cells are 
transfected with pools of multiple siRNAs against single mRNA targets from a list of pro-
migratory genes.  (2) After removal of transfecting agents, source cells are cultured for 48h and 
then the CM is collected and transferred to a multi-well plate assay for assessment of cardiac stem 
cell migration. (3) Migrated stem cells (stained with nuclear Hoechst) are enumerated using a high 
content Cell Analyzer. (4) Data could be integrated with results from other platforms, such as 
Tandem Mass Spectrometry, to perform system analysis of the secretome.  
 
Figure 2:  Paracrine action of pericytes.   Isolated from small surgical leftovers of 
vascular or cardiac tissue, pericytes  are transplanted in the heart or used for valvular tissue 
engineering. They release paracrine factors that (1) improve cardiomyocyte survival and 
inhibit fibrosis, therefore preventing adverse remodelling; (2)  exert proangiogenic activity;   
and (3) promote recruitment of endogenous stem cells. In the case of tissue engineering, 
repopulation of valvular grafts with pericytes may help the renewal of extracellular matrix 
protein s through production and releaseof collagen. 
 
 
Figure 3. Through paracrine mechanisms, c-kit
pos
 heterologous HLA non-matched 
CSC treatment preserves myocardial wall structure and attenuates remodelling in a 
porcine MI model. (A) CSC treatment led to significantly decreased myocyte hypertrophy 
in the border region. *P<0.05 vs. CTRL. (B) Representative H&E staining showing a band 
of hypertrophic myocytes in the border region of CTRL pig myocardium. (C) CSC 
treatment significantly decreased percent number of apoptotic (caspase 3 positive) myocytes 
in the border region. *P<0.05 vs. CTRL. (D & E) Representative images of sirius red 
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staining to identify fibrotic tissue (red) and muscle (yellow) in the infarct region of CTRL 
(D) and CSC-treated (E) pig hearts. (F) CSC-treated pig hearts had a decreased percentage 
area fraction of fibrosis in the infarct zone.*P<0.05 vs. CTRL. 
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Table 1: Cardiovascular preclinical trials using stem cell-derived secretome 
Disease/delivery 
Animal 
model 
Source of CM Outcome Reference 
Limb ischaemia— 
Daily injection of 40 μl of human adipose-
derived stem cell (ADSC) CM for 7 days into 
the gracilis muscle 
Athymic 
mice 
Human adipose-
derived stem cells 
Enhanced endothelial cell growth, CD34
+
 cell 
mobilization from bone marrow, and bone marrow 
cell homing to the ischemic region, resulting in 
improved blood vessel density, limb salvage, and 
blood perfusion. 
(Bhang, Lee 
et al. 2014) 
Limb ischaemia— 
Single injection of human embryonic stem cell-
derived endothelial-like cell  (ESC-EC) CM 
and/or circulating proangiogenic cells (PACs) 
into the gracilis muscle  
SCID mice Human embryonic 
stem cell-derived 
endothelial-like 
cells   
Neither diabetic PACs nor CM from ESC-ECs 
improve blood flow recovery and angiogenesis. In 
contrast, both transplantations of proangiogenic 
cells from controls or diabetic patients 
supplemented with ESC-ECs CM improve blood 
flow and angiogenesis. 
(Ho, Lai et 
al. 2012) 
Limb ischaemia— 
Three weekly intramuscular injections of 
endothelial progenitor cells (EPCs), EPC-CM, 
or control medium 
Athymic 
nude rats  
Human peripheral 
blood endothelial 
progenitor cells 
Both EPC-CM and EPCs increase limb blood flow 
assessed and neovascularization. EPC-CM 
transplantation stimulates the mobilization and 
recruitment of bone marrow-derived EPCs. 
(Di Santo, 
Yang et al. 
2009) 
Limb ischaemia— 
Two intramuscular weekly injections of human 
amniotic liquid derived stem cells (AFSC) CM 
(topically applied to thigh muscles) for a total 
treatment-duration of two weeks 
SCID mice Human amniotic 
liquid derived cKit 
stem cells 
Increased arteriogenesis, capillary density, total 
perfusion area, and mobility. 
(Mirabella, 
Cilli et al. 
2012) 
Myocardial infarction— 
Peri-infarct injection of human adipose-derived 
stem cells (ADSC), ADSC-CM or control 
medium immediately after MI 
SCID and 
C57BL/6 
mice 
Human adipose-
derived stem cells 
Improved cardiac function, reduced infarct size, 
increased reparative angiogenesis, reduced 
cardiomyocyte apoptosis The effect of ADSCs on 
the first 3 outcomes was superior to that of ADSC-
CM.  
(Yang, Wang 
et al. 2013) 
Myocardial infarction— 
Intramyocardial injections of either 
concentrated CM derived from STRO-3- 
mesenchymal precursor cells cultured in 
serum-free medium or control medium at 48 
hrs after MI 
Athymic 
nude rats  
Human STRO-3- 
mesenchymal 
precursor cells 
Improved ventricular function, reduced ventricular 
dilatation, and infarct size, increased 
neovascularization. 
 
(See, Seki et 
al. 2011) 
Myocardial infarction— Pigs Human embryonic Increased capillary density, reduced infarct size  (Timmers, 
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Intravenous treatment with CM from human 
embryonic stem cells-derived MSCs or control 
medium initiated 4 h after coronary artery 
ligation with the treatment continued for 7 
days twice daily via a catheter inserted into the 
jugular vein 
stem cells-derived 
MSCs 
improved myocardial performance. Lim et al. 
2011) 
Myocardial infarction— 
At the end of 2 h reperfusion, three cycles of 
intracoronary infusion CM from porcine 
endothelial progenitor cells or vehicle  
Pigs Porcine peripheral 
blood endothelial 
progenitor cells 
Increased angiogenesis, improved cardiomyocyte 
remodeling and contractility. 
 
(Hynes, 
Kumar et al. 
2013) 
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Table 2: Cardiac stem cells subtypes based on antigenic characteristics 
Subtype cKit CD34 Sca-1 Abcg2 Wt1 CD105 GATA4 MEF2C NKX2-5 CD166 CD45 PDGFRα CD90 FLK1 
c-Kit CSCs + - + + - + + + +/- + - + +/- +/- 
Sca-1 CSCs low - +  +/-  + + low  - +  - 
Side population + + + + +/-  -  -  + +   
Cardiosphere-derived cells low + + +  +     +    
Cardiac resident colony-forming unit-fibroblast low  +  + +     - + + - 
Isl-1pos cardiac progenitor cells -  -    +  +      
Epicardial stem cells -  +  +          
 
C-kit+ CSCs (Beltrami, Barlucchi et al. 2003, Ellison, Vicinanza et al. 2013) Sca1pos CSCs  (Oh, Bradfute et al. 2003); side population (SP) cells) 
(Martin, Meeson et al. 2004); Cardiosphere-derived cells (Chimenti, Gaetani et al. 2012); cardiac resident colony-forming unit-fibroblast (cCFU-
Fs) (Chong, Chandrakanthan et al. 2011); and the Isl-1pos cardiac progenitor cells (Laugwitz, Moretti et al. 2008); Epicardial stem cells (Smart, 
Bollini et al. 2011). 
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Table 3: Pericyte subtypes based on antigenic characteristics 
Subtype CD146 NG2 PDGFRβ PDGFRα CD34 CD45 CD73 CD44 CD105 CD45 cKit CD90 CD26 CD31 
Microvascular pericytes + + +  - -    -     
CD146-pos cardiac pericytes + + + + - - + + + - -   - 
CD146-neg cardiac pericytes - + +  +*  - + + -  low  - 
Adventitial pericyte-like stem cells - + +  +* - + + + -  + + - 
 
Microvascular pericytes (Dellavalle, Maroli et al. 2011, Corselli, Crisan et al. 2013); CD146-pos cardiac pericytes (Chen, Baily et al. 2015); 
CD146-neg cardiac pericytes (Avolio, Rodriguez-Arabaolaza et al. 2015); Adventitial pericyte-like stem cells (Campagnolo, Cesselli et al. 2010, 
Klein, Weisshardt et al. 2011, Chen, Corselli et al. 2012). *CD34 is used for immunomagnetic sorting of adventitial pericyte-like stem cells but the 
antigen is not expressed after culture expansion of the isolated cells. 
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